PRIMALung study has successfully enrolled 150 patients! – EORTC
European Organisation for Research and Treatment of Cancer (EORTC) posted on LinkedIn:
“We are excited to announce that the PRIMALung (EORTC-1901-LCG) study has successfully enrolled 150 patients!
PRIMALung is a pivotal trial in which patients with limited and extensive-stage small-cell lung cancer are randomized 1:1 to receive brain MRI surveillance with or without prophylactic cranial irradiation (PCI) (25 Gy in 10 fractions).
Primary objective: to determine whether brain MRI surveillance alone is non-inferior to brain MRI surveillance combined with PCI in terms of overall survival, an especially critical question in the immunotherapy era.
This achievement is a testament to the unwavering dedication of our Study Coordinators, Prof. Faivre-Finn Corinne and Prof. Antonin Levy, as well as the commitment of all participating centres. A heartfelt thank you to the patients and families involved for their trust and collaboration.
We look forward to continuing this momentum in the next recruitment period. Thank you for being part of this important journey!”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023